The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Shell and Equinor on Tuesday urged a Scottish court to uphold Britain's approval for the development of two vast North Sea ...

JetBlue Airways said late on Monday it will extend a halt to all flights to and from Haiti through Dec. 2 after damage from a ...

If you missed the early fall push for flu and COVID-19 vaccines, it's not too late. It takes the body about two weeks to build up immunity after either shot — meaning vaccination is needed before ...

Novavax (NASDAQ:NVAX) Inc. has reached a settlement with the UK Health Security Agency, agreeing to refund $123.8 million and terminate their existing vaccine supply agreement. The settlement, ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...

At the European Society of Cardiology, Coventry Hospital in the UK presented data on the use of VIVO in very ... Global Clingwrap Machine Market was... Novavax, Inc. , a global company advancing ...

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.